On May 17, 2021, NeuBase Therapeutics, Inc. appointed Dr. Kianoush (Kia) Motesharei, Ph.D., as the company’s Chief Business and Strategy Officer, effective May 24, 2021. There are no reportable family relationships or related party transactions (as defined in Item 404(a) of Regulation S-K) involving the company and Dr. Motesharei. Dr. Motesharei will report to Dr. Dietrich Stephan, the company’s President and Chief Executive Officer. Dr. Motesharei, Ph.D., 51, brings over 20 years of experience in management, strategy, business development, alliance management, product development and marketing across the biotechnology and pharmaceutical industry. Dr. Motesharei was previously the Senior Vice President of Business Development & Corporate Strategy with Akcea Therapeutics during 2020. Before that, he was Vice President, Global Head Licensing & Business Development, Neurology & Immunology at Merck KGaA from 2013 to 2019, Vice President of Business Development & Alliance Management at Dyax from 2011 to 2013, Chief Business Officer at the French biotech company Genfit from 2007 to 2010 and Vice President of Corporate Development at ActivX. Most recently, Dr. Motesharei was Senior Vice President, Business Development & Corporate Strategy at Akcea Therapeutics, a late-stage development and commercial biopharmaceutical company focused on rare diseases, where he led and executed the regional partnership of Akcea's marketed products Tegsedi® and Waylivra® with Sobi in Europe and the Middle East.